Background Obesity hypoventilation syndrome (OHS) is the most common indication for home ventilation, although the optimal therapy remains unclear, particularly for severe disease. We compared Bi-level and continuous positive airways pressure (Bi-level positive airway pressure (PAP); CPAP) for treatment of severe OHS.
Methods We conducted a multicentre, parallel, double-blind trial for initial treatment of OHS, with participants randomised to nocturnal Bi-level PAP or CPAP for 3 months. The primary outcome was frequency of treatment failure (hospital admission, persistent ventilatory failure or non-adherence); secondary outcomes included health-related quality of life (HRQoL) and sleepiness.
Results Sixty participants were randomised; 57 completed follow-up and were included in analysis (mean age 53 years, body mass index 55 kg/m2, PaCO2 60 mm Hg). There was no difference in treatment failure between groups (Bi-level PAP, 14.8% vs CPAP, 13.3%, p=0.87). Treatment adherence and wake PaCO2 were similar after 3 months (5.3 hours/night Bi-level PAP, 5.0 hours/night CPAP, p=0.62; PaCO2 44.2 and 45.9 mm Hg, respectively, p=0.60). Between-group differences in improvement in sleepiness (Epworth Sleepiness Scale 0.3 (95% CI -2.8, 3.4), p=0.86) and HRQoL (Short Form (SF)36-SF6d 0.025 (95% CI -0.039, 0.088), p=0.45) were not significant. Baseline severity of ventilatory failure (PaCO2) was the only significant predictor of persistent ventilatory failure at 3 months (OR 2.3, p=0.03).
Conclusions In newly diagnosed severe OHS, Bi-level PAP and CPAP resulted in similar improvements in ventilatory failure, HRQoL and adherence. Baseline PaCO2 predicted persistent ventilatory failure on treatment. Long-term studies are required to determine whether these treatments have different cost-effectiveness or impact on mortality.
Trial registration number ACTRN12611000874910, results.
- Non invasive ventilation
- Sleep apnoea
Statistics from Altmetric.com
Australian trial finds that CPAP provides similar benefits to non-invasive ventilation in severe obesity hypoventilation syndrome.
Contributors MEH co-developed and drafted the protocol, conducted statistical analysis, recruited participants, drafted the manuscript and generated figures; DJB co-developed and drafted the protocol, wrote the institutional review board application, co-developed analysis, generated the random allocation sequence, assigned participants and edited the manuscript; AJP co-developed and drafted the protocol, co-developed analysis, recruited participants and edited the manuscript; AEH and BJY co-developed the protocol, recruited participants, co-developed analysis and edited the manuscript; DH co-developed the protocol and analysis and edited the manuscript. BS contributed to design, recruited participants, collected and entered data, conducted analysis and edited the manuscript; ED, DM, ATB, DF, CB, LR and NS contributed to design, recruited participants, collected and entered data and edited the manuscript.
Funding This investigator-initiated project was funded by an unrestricted grant from the ResMed Foundation, San Diego, California, USA.
Competing interests MEH reports grants from ResMed Foundation, during the conduct of the study; non-financial support from Philips Respironics, outside the submitted work. AJP reports grants from ResMed Foundation, personal fees from ResMed, personal fees from Philips Respironics, during the conduct of the study; personal fees from SenTec, outside the submitted work. DM reports grants from ResMed Foundation, during the conduct of the study; grants from National Health and Medical Research Council, grants from Victoria Neurotrauma Initiative, outside the submitted work. BS, AEH, BJY, ED, ATB, DF, CB, LR, NS, DH and DJB report a grant from ResMed Foundation, during the conduct of the study.
Ethics approval Austin Health Human Research Ethics Committee.
Provenance and peer review Not commissioned; externally peer reviewed.